📊 GCTK Key Takeaways
Is Glucotrack, Inc. (GCTK) a Good Investment?
Glucotrack is a pre-revenue medical device company with severe operational losses, negative cash flow, and unsustainable unit economics. Despite modest cash reserves relative to burn rate, the company is losing $11.3M annually in operating cash flow on only $2.3K in revenue, indicating fundamental business model failure or complete lack of commercialization.
Glucotrack’s fundamentals remain extremely weak: revenue is effectively negligible, operating losses are very large, and free cash flow is deeply negative. While the company has low leverage and a sizable cash balance relative to its balance sheet, the current burn rate appears unsustainable without additional capital. The reported revenue growth is not high quality because it comes off an immaterial base and does not translate into improving profitability.
Why Buy Glucotrack, Inc. Stock? GCTK Key Strengths
- Positive current ratio of 1.53x provides near-term liquidity cushion
- Maintains cash position of $7.9M to fund operations temporarily
- Zero long-term debt eliminates refinancing risk
- No meaningful long-term debt, which limits balance-sheet leverage risk
- Cash and equivalents of $7.87M provide some near-term funding support
- Current and quick ratios above 1.5x indicate basic short-term liquidity is still intact
GCTK Stock Risks: Glucotrack, Inc. Investment Risks
- Catastrophic operating losses of $12.6M against $2.3K revenue indicates product has not achieved market viability
- Operating cash burn of $11.3M annually with current cash reserves suggests less than 9 months of runway
- Extreme negative profitability ratios (Operating Margin -554,953.8%, Net Margin -693,967.4%) show business model is fundamentally broken
- No insider buying activity in 90 days suggests lack of management confidence
- Revenue growth appears anomalous and unsustainable given massive cash losses
- Revenue base is extremely small at $2.27K, indicating the business is not yet commercially established
- Operating loss of $12.60M and free cash flow of -$11.38M imply heavy ongoing cash burn
- Negative ROE, ROA, and net margin reflect severe structural unprofitability and likely future dilution risk
Key Metrics to Watch
- Monthly cash burn rate and remaining runway
- Revenue trajectory and customer acquisition cost relative to lifetime value
- Path to gross profitability and operating breakeven timeline
- Quarterly revenue scale-up and whether sales become commercially meaningful
- Cash burn runway, especially operating cash flow versus cash balance
Glucotrack, Inc. (GCTK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Glucotrack, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
GCTK Profit Margin, ROE & Profitability Analysis
GCTK vs Healthcare Sector: How Glucotrack, Inc. Compares
How Glucotrack, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Glucotrack, Inc. Stock Overvalued? GCTK Valuation Analysis 2026
Based on fundamental analysis, Glucotrack, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Glucotrack, Inc. Balance Sheet: GCTK Debt, Cash & Liquidity
GCTK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Glucotrack, Inc.'s revenue has declined by 66% over the 5-year period, indicating business contraction. The most recent EPS of $4,106.00 reflects profitable operations.
GCTK Revenue Growth, EPS Growth & YoY Performance
GCTK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2020 | $2.3K | -$509.0K | $0.00 |
| Q2 2020 | $97 | -$574.2K | $0.00 |
| Q1 2020 | $2.2K | -$714.5K | N/A |
| Q3 2019 | $4.2K | -$996.8K | $-0.01 |
| Q2 2019 | $15.3K | -$892.3K | $-0.01 |
| Q1 2019 | $25.6K | $1.0M | N/A |
| Q3 2018 | $20.9K | -$1.6M | $-0.31 |
| Q2 2018 | $8.7K | -$1.9M | $-0.33 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Glucotrack, Inc. Dividends, Buybacks & Capital Allocation
GCTK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Glucotrack, Inc. (CIK: 0001506983)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GCTK
What is the AI rating for GCTK?
Glucotrack, Inc. (GCTK) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 93% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GCTK's key strengths?
Claude: Positive current ratio of 1.53x provides near-term liquidity cushion. Maintains cash position of $7.9M to fund operations temporarily. ChatGPT: No meaningful long-term debt, which limits balance-sheet leverage risk. Cash and equivalents of $7.87M provide some near-term funding support.
What are the risks of investing in GCTK?
Claude: Catastrophic operating losses of $12.6M against $2.3K revenue indicates product has not achieved market viability. Operating cash burn of $11.3M annually with current cash reserves suggests less than 9 months of runway. ChatGPT: Revenue base is extremely small at $2.27K, indicating the business is not yet commercially established. Operating loss of $12.60M and free cash flow of -$11.38M imply heavy ongoing cash burn.
What is GCTK's revenue and growth?
Glucotrack, Inc. reported revenue of $2.3K.
Does GCTK pay dividends?
Glucotrack, Inc. does not currently pay dividends.
Where can I find GCTK SEC filings?
Official SEC filings for Glucotrack, Inc. (CIK: 0001506983) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GCTK's EPS?
Glucotrack, Inc. has a diluted EPS of $30.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GCTK a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Glucotrack, Inc. has a STRONG SELL rating with 93% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GCTK stock overvalued or undervalued?
Valuation metrics for GCTK: ROE of -572.9% (sector avg: 15%), net margin of -693,967.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GCTK stock in 2026?
Our dual AI analysis gives Glucotrack, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GCTK's free cash flow?
Glucotrack, Inc.'s operating cash flow is $-11.3M, with capital expenditures of $76.0K. FCF margin is -501,100.8%.
How does GCTK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -693,967.4% (avg: 12%), ROE -572.9% (avg: 15%), current ratio 1.53 (avg: 2).